Palisade Bio (PALI) EBIAT (2010 - 2026)
Palisade Bio (PALI) reported EBIAT of -$9.6 million for Q1 2026, down 330.49% year-over-year from $4.2 million in Q1 2025, and down 7.88% on a QoQ basis from -$8.9 million in Q4 2025.
Palisade Bio (PALI) has 17 years of EBIAT data on file, last reported at -$9.6 million in Q1 2026.
- Quarterly EBIAT fell 330.49% year-over-year to -$9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (down 83.78% YoY) and the FY2025 annual result came in at -$16.8 million, down 16.23% from the prior year.
- EBIAT declined to -$9.6 million in Q1 2026 per PALI's latest filing, from -$8.9 million in the prior quarter.
- Across five years, EBIAT topped out at -$2.2 million in Q1 2025 and bottomed at -$9.6 million in Q1 2026.
- The 5-year median for EBIAT is -$3.5 million (2024), against an average of -$4.0 million.
- Peak annual rise in EBIAT reached 92.62% in 2022, while the deepest fall reached 446.69% in 2022.
- Tracing PALI's EBIAT over 5 years: stood at -$3.7 million in 2022, then advanced by 20.13% to -$3.0 million in 2023, then dropped by 12.55% to -$3.3 million in 2024, then tumbled by 166.12% to -$8.9 million in 2025, then declined by 7.88% to -$9.6 million in 2026.
- Per Business Quant, the three latest PALI EBIAT figures stand at -$9.6 million (Q1 2026), -$8.9 million (Q4 2025), and -$2.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | -9.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.60 Mn |
| Dec 31, 2025 | -8.90 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | -3.34 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -2.97 Mn |
| Sep 30, 2023 | -3.60 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.72 Mn |
| Sep 30, 2022 | -3.99 Mn |
| Jun 30, 2022 | -2.34 Mn |
| Mar 31, 2022 | -4.21 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 8.09 Mn |
| Jun 30, 2021 | -31.75 Mn |
| Mar 31, 2021 | -4.03 Mn |
| Dec 31, 2020 | -4.24 Mn |
| Sep 30, 2020 | -1.84 Mn |
| Jun 30, 2020 | -1.85 Mn |
| Mar 31, 2020 | -2.38 Mn |
| Dec 31, 2019 | -2.04 Mn |
| Sep 30, 2019 | -1.76 Mn |
| Jun 30, 2019 | -1.44 Mn |
| Mar 31, 2019 | -3.11 Mn |
| Dec 31, 2018 | -320,320.00 |
| Sep 30, 2018 | -1.83 Mn |
| Jun 30, 2018 | -627,046.00 |
| Mar 31, 2018 | -2.15 Mn |
| Dec 31, 2017 | -3.32 Mn |
| Sep 30, 2017 | -133,783.00 |
| Jun 30, 2017 | -4.65 Mn |
| Mar 31, 2017 | -7.57 Mn |
| Dec 31, 2016 | -5.40 Mn |
| Sep 30, 2016 | -5.22 Mn |
| Jun 30, 2016 | -3.85 Mn |
| Mar 31, 2016 | -6.61 Mn |
| Dec 31, 2015 | -4.77 Mn |
| Sep 30, 2015 | -5.64 Mn |
| Jun 30, 2015 | -5.45 Mn |
| Mar 31, 2015 | -5.05 Mn |
| Dec 31, 2014 | -5.50 Mn |
| Sep 30, 2014 | -4.46 Mn |
| Jun 30, 2014 | -6.75 Mn |
| Mar 31, 2014 | -5.92 Mn |
| Dec 31, 2013 | -3.30 Mn |
| Sep 30, 2013 | -6.69 Mn |
| Jun 30, 2013 | -6.25 Mn |
| Mar 31, 2013 | -3.59 Mn |
| Dec 31, 2012 | -2.71 Mn |
| Sep 30, 2012 | -2.58 Mn |
| Jun 30, 2012 | -2.38 Mn |
| Mar 31, 2012 | -2.45 Mn |
| Dec 31, 2011 | -2.56 Mn |
| Sep 30, 2011 | -3.21 Mn |
| Jun 30, 2011 | -3.65 Mn |
| Mar 31, 2011 | -3.10 Mn |
| Dec 31, 2010 | -2.74 Mn |
| Sep 30, 2010 | -3.93 Mn |
| Jun 30, 2010 | -4.95 Mn |